Form 4: Director Han Myung Lee Receives Century Therapeutics Grant

Director Han Myung Lee was granted 74,000 stock options in Century Therapeutics, Inc. as part of standard compensation.

Summary

• Director Han Myung Lee acquired 74,000 stock options in Century Therapeutics, Inc. (IPSC).
• The options have an exercise price of $2.24 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continued service through the earlier of June 11, 2027, or the next annual meeting of stockholders.

Future Outlook

The options vest on the earlier of June 11, 2027, or the next annual meeting of stockholders, assuming continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard corporate governance practices for mid-cap and small-cap biotech firms.
• The vesting schedule is typical for annual director equity awards.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 11, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Century Therapeutics, IPSC, Form 4, Insider Trading, Stock Options, Director Compensation